KR20090053967A - 웨스트 나일 백신 - Google Patents

웨스트 나일 백신 Download PDF

Info

Publication number: KR20090053967A
Authority: KR; South Korea
Prior art keywords: vaccine; virus; west nile; composition; volume
Prior art date: 2001-07-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

KR1020097010065A

Other languages

English (en)

Korean (ko)

Inventor

지엔-주에 주

Original Assignee

와이어쓰

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-27

Filing date

2002-07-23

Publication date

2009-05-28

2002-07-23 Application filed by 와이어쓰 filed Critical 와이어쓰

2009-05-28 Publication of KR20090053967A publication Critical patent/KR20090053967A/ko

Status Ceased legal-status Critical Current

Links

229960005486 vaccine Drugs 0.000 title claims abstract description 93
241000710886 West Nile virus Species 0.000 claims abstract description 74
239000000203 mixture Substances 0.000 claims abstract description 69
239000003921 oil Substances 0.000 claims abstract description 46
239000002671 adjuvant Substances 0.000 claims abstract description 32
238000000034 method Methods 0.000 claims abstract description 27
239000013612 plasmid Substances 0.000 claims abstract description 21
PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims abstract description 18
229920001400 block copolymer Polymers 0.000 claims abstract description 9
JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims abstract description 9
229940032094 squalane Drugs 0.000 claims abstract description 9
-1 Polyoxyethylene Polymers 0.000 claims abstract description 8
239000003937 drug carrier Substances 0.000 claims abstract description 7
229920003171 Poly (ethylene oxide) Polymers 0.000 claims abstract description 5
229920001451 polypropylene glycol Polymers 0.000 claims abstract description 3
230000001900 immune effect Effects 0.000 claims abstract 2
241000283086 Equidae Species 0.000 claims description 66
241000700605 Viruses Species 0.000 claims description 44
241000283073 Equus caballus Species 0.000 claims description 18
201000006449 West Nile encephalitis Diseases 0.000 claims description 7
239000002270 dispersing agent Substances 0.000 claims description 7
239000002736 nonionic surfactant Substances 0.000 claims description 7
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 7
229920000053 polysorbate 80 Polymers 0.000 claims description 7
238000009736 wetting Methods 0.000 claims description 7
239000000080 wetting agent Substances 0.000 claims description 7
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 6
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 5
229960000814 tetanus toxoid Drugs 0.000 claims description 4
238000002560 therapeutic procedure Methods 0.000 claims description 4
241000712461 unidentified influenza virus Species 0.000 claims description 4
241000710945 Eastern equine encephalitis virus Species 0.000 claims description 2
241000701081 Equid alphaherpesvirus 1 Species 0.000 claims description 2
241000701089 Equid alphaherpesvirus 4 Species 0.000 claims description 2
241000230501 Equine herpesvirus sp. Species 0.000 claims description 2
241000604972 Neorickettsia risticii Species 0.000 claims description 2
241000711798 Rabies lyssavirus Species 0.000 claims description 2
241000194017 Streptococcus Species 0.000 claims description 2
241000194048 Streptococcus equi Species 0.000 claims description 2
241000710951 Western equine encephalitis virus Species 0.000 claims description 2
150000002148 esters Chemical class 0.000 claims description 2
230000004936 stimulating effect Effects 0.000 claims description 2
230000000638 stimulation Effects 0.000 claims description 2
208000007514 Herpes zoster Diseases 0.000 claims 2
229940124856 vaccine component Drugs 0.000 claims 2
229920001214 Polysorbate 60 Polymers 0.000 claims 1
241000710959 Venezuelan equine encephalitis virus Species 0.000 claims 1
230000002155 anti-virotic effect Effects 0.000 claims 1
229940049964 oleate Drugs 0.000 claims 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
241001529453 unidentified herpesvirus Species 0.000 claims 1
230000002163 immunogen Effects 0.000 abstract description 21
239000004480 active ingredient Substances 0.000 abstract description 16
201000010099 disease Diseases 0.000 abstract description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
206010014599 encephalitis Diseases 0.000 abstract description 5
208000000832 Equine Encephalomyelitis Diseases 0.000 abstract 1
235000019198 oils Nutrition 0.000 description 29
241001465754 Metazoa Species 0.000 description 20
238000002255 vaccination Methods 0.000 description 18
238000012360 testing method Methods 0.000 description 17
206010058874 Viraemia Diseases 0.000 description 15
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 12
210000001519 tissue Anatomy 0.000 description 10
210000004027 cell Anatomy 0.000 description 9
210000001175 cerebrospinal fluid Anatomy 0.000 description 9
239000000427 antigen Substances 0.000 description 7
102000036639 antigens Human genes 0.000 description 7
108091007433 antigens Proteins 0.000 description 7
239000000839 emulsion Substances 0.000 description 7
241000271566 Aves Species 0.000 description 6
241000255925 Diptera Species 0.000 description 6
210000004556 brain Anatomy 0.000 description 6
241000124008 Mammalia Species 0.000 description 5
230000002238 attenuated effect Effects 0.000 description 5
239000007758 minimum essential medium Substances 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
108010041986 DNA Vaccines Proteins 0.000 description 4
229940021995 DNA vaccine Drugs 0.000 description 4
238000009472 formulation Methods 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
238000002955 isolation Methods 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
238000005259 measurement Methods 0.000 description 4
230000004044 response Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
230000001052 transient effect Effects 0.000 description 4
210000003501 vero cell Anatomy 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
229930193140 Neomycin Natural products 0.000 description 3
108010093965 Polymyxin B Proteins 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
206010057293 West Nile viral infection Diseases 0.000 description 3
239000000872 buffer Substances 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
238000001914 filtration Methods 0.000 description 3
230000028993 immune response Effects 0.000 description 3
230000002779 inactivation Effects 0.000 description 3
229960004927 neomycin Drugs 0.000 description 3
229920000024 polymyxin B Polymers 0.000 description 3
229960005266 polymyxin b Drugs 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
239000012266 salt solution Substances 0.000 description 3
210000000278 spinal cord Anatomy 0.000 description 3
239000000126 substance Substances 0.000 description 3
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 3
229940033663 thimerosal Drugs 0.000 description 3
239000003104 tissue culture media Substances 0.000 description 3
238000011282 treatment Methods 0.000 description 3
241000283074 Equus asinus Species 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
206010033799 Paralysis Diseases 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
210000000133 brain stem Anatomy 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000036755 cellular response Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000002649 immunization Methods 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
239000002609 medium Substances 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
230000000926 neurological effect Effects 0.000 description 2
238000006386 neutralization reaction Methods 0.000 description 2
230000007170 pathology Effects 0.000 description 2
229920001983 poloxamer Polymers 0.000 description 2
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000000405 serological effect Effects 0.000 description 2
210000000605 viral structure Anatomy 0.000 description 2
229960004854 viral vaccine Drugs 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
241000256173 Aedes albopictus Species 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
206010003399 Arthropod bite Diseases 0.000 description 1
NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
241000282552 Chlorocebus aethiops Species 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241000710831 Flavivirus Species 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
206010024264 Lethargy Diseases 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
239000012124 Opti-MEM Substances 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
208000002667 Subdural Hematoma Diseases 0.000 description 1
206010042364 Subdural haemorrhage Diseases 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
239000007984 Tris EDTA buffer Substances 0.000 description 1
206010000210 abortion Diseases 0.000 description 1
231100000176 abortion Toxicity 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
230000001775 anti-pathogenic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229940031567 attenuated vaccine Drugs 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
230000008512 biological response Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
229940001442 combination vaccine Drugs 0.000 description 1
239000002131 composite material Substances 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
230000001788 irregular Effects 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006166 lysate Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
230000001617 migratory effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
235000011056 potassium acetate Nutrition 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
229960000380 propiolactone Drugs 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000010686 shark liver oil Substances 0.000 description 1
229940069764 shark liver oil Drugs 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000008234 soft water Substances 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
238000004448 titration Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
210000004885 white matter Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Mycology (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Dispersion Chemistry (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

KR1020097010065A 2001-07-27 2002-07-23 웨스트 나일 백신 Ceased KR20090053967A (ko)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US30833401P	2001-07-27	2001-07-27
US60/308,334		2001-07-27

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
KR10-2004-7001202A Division KR20040028952A (ko)	2001-07-27	2002-07-23	웨스트 나일 백신

Publications (1)

Publication Number	Publication Date
KR20090053967A true KR20090053967A (ko)	2009-05-28

Family

ID=27613166

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
KR1020097010065A Ceased KR20090053967A (ko)	2001-07-27	2002-07-23	웨스트 나일 백신
KR10-2004-7001202A Ceased KR20040028952A (ko)	2001-07-27	2002-07-23	웨스트 나일 백신

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
KR10-2004-7001202A Ceased KR20040028952A (ko)	2001-07-27	2002-07-23	웨스트 나일 백신

Country Status (24)

Country	Link
US (8)	US7153513B2 (2)
EP (3)	EP2281572A1 (2)
JP (2)	JP4718778B2 (2)
KR (2)	KR20090053967A (2)
CN (2)	CN1273189C (2)
AU (1)	AU2002365244B2 (2)
BE (1)	BE2014C006I2 (2)
BR (1)	BRPI0211492B1 (2)
CA (1)	CA2452545C (2)
CY (1)	CY2014010I2 (2)
DK (1)	DK1427444T3 (2)
ES (1)	ES2435095T3 (2)
FR (1)	FR14C0016I2 (2)
HR (1)	HRP20040195B1 (2)
HU (2)	HU228690B1 (2)
LU (1)	LU92348I2 (2)
ME (1)	ME00491B (2)
MX (1)	MXPA04000680A (2)
NZ (3)	NZ570270A (2)
PL (2)	PL212212B1 (2)
PT (1)	PT1427444E (2)
RS (1)	RS53184B (2)
WO (1)	WO2003061555A2 (2)
ZA (1)	ZA200401596B (2)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7425437B2 (en) *	1999-11-26	2008-09-16	Crucell Holland B.V.	Vaccines against West Nile Virus
RS53184B (sr) *	2001-07-27	2014-06-30	Zoetis W Llc	Kompozicija vakcine za primenu u sprečavanju ili ublažavanju encefalitisa zapadnog nila kod ekvida
WO2005024427A2 (en) *	2003-09-09	2005-03-17	Idexx Laboratories, Inc.	Detection of west nile virus infection and vaccination
US7074555B2 (en) *	2004-04-28	2006-07-11	Idexx Laboratories, Inc.	Detection of West Nile Virus
FR2870126B1 (fr)	2004-05-17	2009-07-17	Pasteur Institut	Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
US7482017B2 (en)	2004-09-09	2009-01-27	Research Development Foundation	Flavivirus variants having phenotypic variation and immunogenic compositions thereof
WO2006107655A2 (en) *	2005-04-01	2006-10-12	Wyeth	Use of wnv dna vaccine in combination with a conventional vaccine to overcome immunogen interference
US11865172B2 (en)	2005-04-21	2024-01-09	University Of Florida Research Foundation, Inc.	Materials and methods for respiratory disease control in canines
US7959929B2 (en)	2005-04-21	2011-06-14	University Of Florida Research Foundation, Inc.	Materials and methods for respiratory disease control in canines
AU2006245734C1 (en)	2005-05-12	2012-05-24	Crucell Holland B.V.	Host cell specific binding molecules capable of neutralizing viruses and uses thereof
WO2006122964A1 (en) *	2005-05-19	2006-11-23	Crucell Holland B.V.	Methods for the production of a whole-inactivated west nile virus vaccine
EP1724338A1 (en) *	2005-05-19	2006-11-22	Crucell Holland B.V.	Methods for the production of a whole-inactivated West Nile Virus vaccine
EP1896069B1 (en) *	2005-06-24	2013-03-13	Intervet International BV	Inactivated chimeric vaccines and related methods of use
ES2496315T3 (es) *	2005-10-19	2014-09-18	University Of Florida Research Foundation, Incorporated	Materiales para el control de la enfermedad respiratoria en caninos
WO2007047728A2 (en) *	2005-10-20	2007-04-26	Wyeth	Compositions and methods for the treatment of canine influenza virus disease
AU2006338210A1 (en) *	2005-12-14	2007-08-23	The Board Of Regents Of The University Of Oklahoma	RNA virus vaccines and methods
WO2007141274A2 (en) *	2006-06-06	2007-12-13	Crucell Holland B.V.	Human binding molecules having killing activity against staphylococci and uses thereof
EP2217271B1 (en) *	2007-11-06	2016-05-04	Zoetis Services LLC	Mycoplasma hyopneumoniae avirulent -adjuvanted live vaccine
AU2009248810B2 (en)	2008-05-23	2013-12-05	The Regents Of The University Of Michigan	Nanoemulsion vaccines
CA2732035A1 (en) *	2008-07-30	2010-02-04	University Of Kentucky Research Foundation	Equine disease model for herpesvirus neurologic disease and uses thereof
CA2735164C (en) *	2008-08-29	2021-08-31	Boehringer Ingelheim Vetmedica, Inc.	West nile virus vaccine
BR112012008185A2 (pt) *	2009-10-07	2016-08-16	Wyeth Llc	composições que compreendem adjuvante, macrolídeo e antígeno proteináceo, e métodos para uso dessas composições
EP2772266B1 (en)	2011-03-14	2019-07-31	Boehringer Ingelheim Animal Health USA Inc.	Equine Rhinitis vaccine
CN103045544B (zh) *	2011-10-17	2015-01-14	华中农业大学	预防西尼罗河病毒的重组假型杆状病毒Bac-G-prM/E及疫苗与应用
HK1219426A1 (zh) *	2013-05-14	2017-04-07	Zoetis Services Llc	包含免疫刺激性寡核苷酸的新穎疫苗組合物
MX2016002903A (es) *	2013-09-05	2016-06-06	Zoetis Services Llc	Composiciones inmunogenas de la glicoproteina g de los virus hendra y nipah.
WO2017210215A1 (en)	2016-05-31	2017-12-07	The Government Of The United States Of America As Represented By The Secretary Of The Army	Zika virus vaccine and methods of production
PL70842Y1 (pl) *	2017-08-25	2019-06-28	Gondek Lukasz Kuznia Mocy	Urządzenie do regeneracji filtrów cząstek stałych i katalizatorów samochodowych
CN113905759A (zh)	2019-02-27	2022-01-07	罗切斯特大学	用于预防和控制马的马流感病毒(eiv)的多价减毒活流感疫苗

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US308334A (en)		1884-11-18		Ladder
US6184024B1 (en)	1988-07-14	2001-02-06	The United States Of America As Represented By The Department Of Health And Human Services	Chimeric and/or growth-restricted flaviviruses
US5741696A (en) *	1992-08-07	1998-04-21	Syntro Corporation	Recombinant equine herpesviruses
FR2702373B1 (fr) *	1993-03-08	1996-06-07	Rhone Merieux	Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
PT968722E (pt) *	1994-05-10	2007-09-06	Wyeth Corp	Vacina viva melhorada contra brsv.
US7227011B2 (en)	1998-06-04	2007-06-05	United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention	Nucleic acid vaccines for prevention of flavivirus infection
US7417136B1 (en)	1998-06-04	2008-08-26	The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention	Nucleic acid vaccines for prevention of flavivirus infection
AU1152402A (en)	2000-10-04	2002-04-15	Univ Pennsylvania	Highly expressible genes
WO2002068637A2 (en)	2000-10-20	2002-09-06	Ribozyme Pharmaceuticals, Inc.	Nucleic acid-based treatment of diseases or conditions related to west nile virus infection
US20050048073A1 (en)	2001-02-28	2005-03-03	De Groot Anne S.	Methods of determining west nile virus epitopes and method of using the same
WO2002072036A2 (en) *	2001-03-12	2002-09-19	Yale University	Compositions and methods comprising west nile virus polypeptides
US20030104008A1 (en) *	2001-04-06	2003-06-05	Loosmore Sheena May	Recombinant vaccine against west nile virus
FR2823222B1 (fr) *	2001-04-06	2004-02-06	Merial Sas	Vaccin contre le virus de la fievre du nil
RS53184B (sr) *	2001-07-27	2014-06-30	Zoetis W Llc	Kompozicija vakcine za primenu u sprečavanju ili ublažavanju encefalitisa zapadnog nila kod ekvida
AU2003263853A1 (en)	2002-08-16	2004-03-03	Board Of Regents The University Of Texas System	Compositions and methods related to flavivirus envelope protein domain iii antigens

2002
- 2002-07-23 RS YU8004A patent/RS53184B/sr unknown
- 2002-07-23 CN CNB028146646A patent/CN1273189C/zh not_active Expired - Lifetime
- 2002-07-23 AU AU2002365244A patent/AU2002365244B2/en not_active Expired
- 2002-07-23 CN CN2006101058113A patent/CN1935258B/zh not_active Expired - Lifetime
- 2002-07-23 KR KR1020097010065A patent/KR20090053967A/ko not_active Ceased
- 2002-07-23 EP EP10183615A patent/EP2281572A1/en not_active Withdrawn
- 2002-07-23 PL PL368535A patent/PL212212B1/pl unknown
- 2002-07-23 BR BRPI0211492A patent/BRPI0211492B1/pt active IP Right Grant
- 2002-07-23 EP EP02806585.2A patent/EP1427444B1/en not_active Expired - Lifetime
- 2002-07-23 ME MEP-2008-784A patent/ME00491B/me unknown
- 2002-07-23 PT PT2806585T patent/PT1427444E/pt unknown
- 2002-07-23 PL PL398575A patent/PL220846B1/pl unknown
- 2002-07-23 NZ NZ570270A patent/NZ570270A/en not_active Application Discontinuation
- 2002-07-23 JP JP2003561501A patent/JP4718778B2/ja not_active Expired - Lifetime
- 2002-07-23 KR KR10-2004-7001202A patent/KR20040028952A/ko not_active Ceased
- 2002-07-23 ES ES02806585T patent/ES2435095T3/es not_active Expired - Lifetime
- 2002-07-23 EP EP10183676A patent/EP2283858A3/en not_active Ceased
- 2002-07-23 WO PCT/US2002/023447 patent/WO2003061555A2/en not_active Ceased
- 2002-07-23 MX MXPA04000680A patent/MXPA04000680A/es active IP Right Grant
- 2002-07-23 DK DK02806585.2T patent/DK1427444T3/da active
- 2002-07-23 CA CA2452545A patent/CA2452545C/en not_active Expired - Lifetime
- 2002-07-23 HR HRP20040195AA patent/HRP20040195B1/hr not_active IP Right Cessation
- 2002-07-23 HU HU0401606A patent/HU228690B1/hu active Protection Beyond IP Right Term
- 2002-07-23 NZ NZ531265A patent/NZ531265A/en not_active IP Right Cessation
- 2002-07-25 US US10/202,716 patent/US7153513B2/en not_active Expired - Lifetime
2004
- 2004-02-26 ZA ZA2004/01596A patent/ZA200401596B/en unknown
2006
- 2006-10-30 US US11/589,528 patent/US7648706B2/en not_active Expired - Lifetime
- 2006-10-30 US US11/589,515 patent/US20070166324A1/en not_active Abandoned
- 2006-10-30 US US11/589,595 patent/US20070231350A1/en not_active Abandoned
- 2006-10-30 US US11/589,523 patent/US20070166326A1/en not_active Abandoned
- 2006-10-30 US US11/589,527 patent/US7445787B2/en not_active Expired - Lifetime
- 2006-10-30 US US11/589,507 patent/US7648705B2/en not_active Expired - Lifetime
- 2006-10-30 US US11/589,516 patent/US20070166325A1/en not_active Abandoned
2007
- 2007-02-13 NZ NZ553165A patent/NZ553165A/en not_active IP Right Cessation
2010
- 2010-11-15 JP JP2010255105A patent/JP2011057692A/ja active Pending
2013
- 2013-10-04 HU HUS1300055C patent/HUS1300055I1/hu unknown
2014
- 2014-01-06 LU LU92348C patent/LU92348I2/xx unknown
- 2014-01-31 BE BE2014C006C patent/BE2014C006I2/fr unknown
- 2014-02-20 CY CY2014010C patent/CY2014010I2/el unknown
- 2014-02-21 FR FR14C0016C patent/FR14C0016I2/fr active Active

Also Published As

Publication number	Publication date
BE2014C006I2 (2)	2021-02-04
YU8004A (sh)	2006-08-17
CY2014010I2 (el)	2024-02-16
CN1935258B (zh)	2013-04-03
FR14C0016I1 (2)	2014-03-28
US20070178119A1 (en)	2007-08-02
WO2003061555A2 (en)	2003-07-31
JP2011057692A (ja)	2011-03-24
HUS1300055I1 (hu)	2016-08-29
EP2283858A3 (en)	2011-03-23
BRPI0211492B1 (pt)	2016-06-21
CN1935258A (zh)	2007-03-28
PL368535A1 (en)	2005-04-04
US7648705B2 (en)	2010-01-19
EP2283858A2 (en)	2011-02-16
MXPA04000680A (es)	2004-04-05
US20070166325A1 (en)	2007-07-19
PL398575A1 (pl)	2012-06-18
US7648706B2 (en)	2010-01-19
US20030091595A1 (en)	2003-05-15
DK1427444T3 (da)	2013-11-04
RS53184B (sr)	2014-06-30
HK1066470A1 (en)	2005-03-24
KR20040028952A (ko)	2004-04-03
US20070166324A1 (en)	2007-07-19
PL212212B1 (pl)	2012-08-31
HUP0401606A3 (en)	2005-02-28
ME00491B (me)	2011-10-10
US20070166802A1 (en)	2007-07-19
ZA200401596B (en)	2005-07-27
PL220846B1 (pl)	2016-01-29
PT1427444E (pt)	2013-11-19
US7153513B2 (en)	2006-12-26
AU2002365244B2 (en)	2007-12-06
HRP20040195B1 (hr)	2014-07-18
HUP0401606A2 (hu)	2004-11-29
CA2452545C (en)	2015-06-09
CN1535157A (zh)	2004-10-06
US7445787B2 (en)	2008-11-04
CA2452545A1 (en)	2003-07-31
BR0211492A (pt)	2004-08-17
NZ570270A (en)	2010-08-27
CN1273189C (zh)	2006-09-06
NZ531265A (en)	2008-08-29
US20070231349A1 (en)	2007-10-04
WO2003061555A3 (en)	2004-04-15
EP2281572A1 (en)	2011-02-09
HU228690B1 (en)	2013-05-28
LU92348I2 (fr)	2014-09-22
CY2014010I1 (el)	2020-05-29
FR14C0016I2 (fr)	2015-07-24
EP1427444A2 (en)	2004-06-16
EP1427444B1 (en)	2013-08-21
ES2435095T3 (es)	2013-12-18
US20070231350A1 (en)	2007-10-04
NZ553165A (en)	2008-09-26
JP2005515236A (ja)	2005-05-26
US20070166326A1 (en)	2007-07-19
HRP20040195A2 (en)	2004-08-31
EP1427444A4 (en)	2008-01-02
LU92348I9 (2)	2019-01-02
JP4718778B2 (ja)	2011-07-06

Legal Events

Date	Code	Title	Description
2009-05-15	A107	Divisional application of patent
2009-05-15	PA0104	Divisional application for international application	Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20090515
2009-05-28	PG1501	Laying open of application
2009-06-12	A201	Request for examination
2009-06-12	PA0201	Request for examination	Patent event code: PA02012R01D Patent event date: 20090612 Comment text: Request for Examination of Application
2009-08-11	E902	Notification of reason for refusal
2009-08-11	PE0902	Notice of grounds for rejection	Comment text: Notification of reason for refusal Patent event date: 20090811 Patent event code: PE09021S01D
2010-02-11	AMND	Amendment
2010-04-19	E601	Decision to refuse application
2010-04-19	PE0601	Decision on rejection of patent	Patent event date: 20100419 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20090811 Comment text: Notification of reason for refusal Patent event code: PE06011S01I
2010-07-20	J201	Request for trial against refusal decision
2010-07-20	PJ0201	Trial against decision of rejection	Patent event date: 20100720 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20100419 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 20110504 Appeal identifier: 2010101005518 Request date: 20100720
2010-08-19	AMND	Amendment
2010-08-27	PB0901	Examination by re-examination before a trial	Comment text: Amendment to Specification, etc. Patent event date: 20100819 Patent event code: PB09011R02I Comment text: Request for Trial against Decision on Refusal Patent event date: 20100720 Patent event code: PB09011R01I Comment text: Amendment to Specification, etc. Patent event date: 20100211 Patent event code: PB09011R02I
2010-09-02	B601	Maintenance of original decision after re-examination before a trial
2010-09-02	PB0601	Maintenance of original decision after re-examination before a trial	Comment text: Report of Result of Re-examination before a Trial Patent event code: PB06011S01D Patent event date: 20100902
2011-05-04	J301	Trial decision	Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20100720 Effective date: 20110504
2011-05-04	PJ1301	Trial decision	Patent event code: PJ13011S01D Patent event date: 20110504 Comment text: Trial Decision on Objection to Decision on Refusal Appeal kind category: Appeal against decision to decline refusal Request date: 20100720 Decision date: 20110504 Appeal identifier: 2010101005518

Publication	Publication Date	Title
KR20090053967A (ko)	2009-05-28	웨스트 나일 백신
Baer et al.	1972	A model in mice for the pathogenesis and treatment of rabies
AU2002365244A1 (en)	2003-09-18	West nile vaccine
JPH10114678A (ja)	1998-05-06	改良型不活化ワクチン
EP1154792B1 (en)	2006-10-11	Tuberculosis vaccine formulation comprising monoglycerides or fatty acids as adjuvant
HK1066470B (en)	2014-04-11	West nile vaccine
BR122015019697B1 (pt)	2018-09-18	composição de vacina para west nile, e uso de plasmídeo com inserções de sequência de dna de vírus west nile na preparação da mesma
US20060222660A1 (en)	2006-10-05	Use of DNA vaccine in combination with a conventional vaccine to overcome immunogen interference
CS231514B1 (cs)	1984-11-19	Inaktivovaná olejová vakcína proti Aujeszkyho chorobě a sposob jej výroby